Regulus floats after slashing IPO price but partner placements add to tally
This article was originally published in Scrip
Regulus Therapeutics sold 11.25 million shares of common stock at $4 per share on 4 October - one-third of its earlier expectation of $10 to $12 per share - when its initial public offering debuted on the Nasdaq, but the company raised $70 million in total thanks to a concurrent private placement of 6.25 million shares with its partner AstraZeneca.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.